Advertisement

NLS Business

Business - October 19, 2022

An end-to-end neurocentric company

This up-and-coming star on the global biotech scene aims to crack the hard code of finding better treatments for neurodegenerative diseases. The name of the company, Muna, means “to remember” in Old Norse and reflects the focus of discovering and developing medicines for neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Multiple Sclerosis and Frontotemporal Dementia. These are […]

Business - October 11, 2022

Unlocking the full value potential in digital pathology

DoMore Diagnostics, one of our NLS Stars 2022, aims to change the one-size-fits-all approach in cancer therapy. Cancer is a growing global public health problem, and the cost of cancer care is expected to double the next 20 years. It is a leading cause of death worldwide and accounted for nearly 10 million deaths in […]

Business - September 30, 2022

Umeå Biotech Incubator launches international incubator program

Umeå Biotech Incubator (UBI) is launching the ‘UBI International Coaching Program’, with the first course starting on October 24th. “If you strive to be one of the world’s best incubators you must have the whole world as your marketplace”, says Jennie Ekbeck, CEO of UBI. “Our role is to help companies develop solutions that meet […]

Business - September 29, 2022

Q&A: Kaiku Health – from startup to acquisition

Two years ago Finnish health tech company Kaiku Health was acquired by Elekta, the global leader in radiotherapy technology. NLS asked Lauri Sippola, co-founder and CEO of Kaiku Health, about the company’s journey and his best advice to other entrepreneurs. Kaiku Health, based in Helsinki, is a great example of Finnish strengths in nurturing and […]

Biotech Business - August 31, 2022

Interview: Erik Manting, CEO, Mendus

Earlier this summer Immunicum announced a corporate rebranding and name change to Mendus and most recently the company reported financing commitments totaling up to 250 million SEK. NLS asked Erik Manting, CEO, about what lies ahead. What opportunities do you have on the market for cancer immunotherapy? “Many cancer patients today experience an initial treatment […]

Business - May 18, 2022

Business Interview: At the forefront of clinical cell therapy

XNK Therapeutics recently secured a private placement of 132 million SEK, enabling progress of the company’s development of new NK cell-based therapies. Since its foundation ten years ago, Swedish XNK Therapeutics has been developing novel autologous natural killer (NK) cell-based therapies targeting cancer. The company’s technology platform includes assets related to the investigational drug product […]

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.